After cardiotoxic therapy for breast cancer, two factors help identify women at particular risk, researchers say.
The two markers -- cardiac troponin and longitudinal strain on echocardiography -- helped show which women were most likely to have cardiotoxicity within 6 months after anthracycline or trastuzumab treatment for breast cancer, in a study reported online March 2nd in the American Journal of Cardiology....
Žádné komentáře:
Okomentovat
Poznámka: Komentáře mohou přidávat pouze členové tohoto blogu.